Catalog No.
Product Name
Application
Product Information
Citations
-
PAFR antagonist
Ginkgolide B (BN 52021) is a PAFR antagonist with IC50 of 3.6 μM. -
PAFR inhibitor/H1 receptor inhibitor
Rupatadine is an inhibitor of PAFR and histamine (H1) receptor with Ki of 550 and 102 nM, respectively. -
PAF antagonist
Aglafoline is an effective PAF antagonist not only in vitro, but also in vivo. -
PAFR inhibitor/H1 receptor inhibitor
Rupatadine is an inhibitor of PAFR and histamine (H1) receptor with Ki of 550 and 102 nM, respectively. -
PAF receptor antagonist
Foropafant (SR27417) highly potent, competitive, selective and orally active antagonist of platelet-activating factor (PAF) receptor. -
PAF antagonist
Ro 24-4736 is a potent, selective, p.o.-active platelet-activating factor (PAF) antagonist with a long duration of action. -
thromboxane synthesis inhibitor
Ro-24-0238 is an antagonist of platelet activating factor (PAF) and inhibitor of thromboxane synthesis, used for lessening the inflammation and damage resulting from a local release of PAF. -
antiplatelet activities
6-Methoxydihydroavicine is an alkaloid isolated from Zanthoxylum integrifoliolum. 6-Methoxydihydroavicine has antiplatelet activities and inhibits AA-, collagen- and PAF-induced platelet aggregation in vitro. -
PAF activator
C16-PAF (PAF (C16)) is a phospholipid mediator and a potent platelet-activating factor that functions as a ligand for the PAF G-protein-coupled receptor (PAFR). It exhibits anti-apoptotic effects by inhibiting caspase-dependent cell death through PAFR activation. C16-PAF is a strong activator of the MAPK and MEK/ERK signaling pathways and is known to induce increased vascular permeability. -
PAF receptor antagonist
ST-899 is a specific antagonist of the platelet-activating factor (PAF) receptor, demonstrating significant efficacy in reducing mortality in endotoxin (LPS)-induced shock models in mice. This compound effectively inhibits the elevation of serum tumor necrosis factor (TNF) levels triggered by LPS while showing no impact on interleukin-6 (IL-6) levels. By interrupting the positive feedback loop between PAF and TNF, ST-899 mitigates the inflammatory response. This reagent is valuable for research into inflammatory diseases, particularly septic shock. -
Platelet Aggregation Inhibitor
Epoprostenol sodium, a synthetic derivative of prostaglandin I2, primarily acts as a potent inhibitor of platelet aggregation. This compound is widely recognized for its role in the management of pulmonary arterial hypertension (PAH) and is utilized in clinical settings such as pulmonary hypertension and organ transplantation. Its ability to modulate vasodilation and inhibit platelet activation makes it a valuable tool in related biomedical research applications. -
Platelet Aggregation Inhibitor
2'-Hydroxyflavanone is a flavanone that functions as a platelet aggregation inhibitor. It demonstrates significant bioactivity by inhibiting platelet aggregation induced by arachidonic acid and adenosine diphosphate, with IC50 values of 47.8 μM and 147.2 μM, respectively. Additionally, 2'-hydroxyflavanone has been implicated in inhibiting cancer cell proliferation and inducing apoptosis, making it valuable for research in cancer and inflammatory pathways. -
PAF Antagonist
Pinusolide is a potent antagonist of the platelet-activating factor (PAF) receptor, critically involved in inflammatory responses and cancer progression. This compound has been shown to inhibit tumor cell proliferation and to induce apoptosis, making it a valuable tool in cancer research. Pinusolide's unique mechanism of action provides insights into PAF-related signaling pathways and potential therapeutic strategies. -
Platelet Aggregation Inhibitor
Ergosta-7,22-dien-3-one functions as a platelet aggregation inhibitor, derived from the fruiting bodies of Ganoderma lucidum. This compound is known to enhance nitric oxide production and promote the expression of specific genes alongside the synthesis of Toll-like receptors (TLRs), cytokines, chemokines, and cellular adhesion molecules in vitro. Ergosta-7,22-dien-3-one is valuable for research in hematology, inflammation, and cellular signaling pathways. -
Platelet Aggregation Inhibitor
5(S),15(S)-DiHETE is a platelet aggregation inhibitor that functions as an activated intermediate in the biosynthesis of specialized pro-resolving mediators. With an IC50 of 1.3 μM, it effectively reduces platelet aggregation. Additionally, 5(S),15(S)-DiHETE enhances the rate of biosynthesis for lipoxins A4 (LXA4) and B4 (LXB4), making it valuable for research applications in inflammation and resolution processes. -
PAF/Histamine Antagonist
Sch-40338 is a dual antagonist targeting platelet-activating factor (PAF) and histamine, exhibiting an IC50 of 0.59 μM in PAF-induced platelet aggregation and a Ki of 5.4 μM for histamine H₁ receptor binding. This compound is valuable for investigating the mechanisms underlying allergic diseases, offering insights into the modulation of inflammatory responses and platelet activation pathways. Sch-40338 serves as a useful tool for researchers exploring therapeutic strategies in allergen-mediated conditions. -
PAF/Histamine Antagonist
N-Acetyldesloratadine is a potent dual antagonist of platelet-activating factor (PAF) and histamine, exhibiting oral bioactivity. It effectively inhibits PAF-induced aggregation of human platelets with an IC50 value of 0.6 µM. This compound is valuable for research into allergic diseases, including asthma, due to its ability to modulate PAF and histamine pathways. -
Platelet Aggregation Inhibitor
12(S)-HETrE is a fatty acid metabolite that serves as a potent inhibitor of platelet aggregation. This compound demonstrates significant biological activity in modulating thrombus formation and is valuable in thrombosis-related research applications. Researchers can utilize 12(S)-HETrE to study the molecular mechanisms underlying platelet function and explore potential therapeutic targets in cardiovascular diseases. -
PAF Antagonist
Dersalazine sodium is a platelet-activating factor (PAF) antagonist that demonstrates significant anti-inflammatory properties in intestinal models. It has been shown to effectively downregulate IL-17 expression in rodent colitis studies, making it a valuable tool for investigating inflammatory bowel disease and related conditions. Its mechanism of action allows for exploration of PAF-related pathways in various biological contexts. -
Platelet Aggregation Inhibitor
Notoginsenoside Fc is a protopanaxadiol-type saponin derived from the leaves of Panax notoginseng, functioning primarily as a platelet aggregation inhibitor. This compound effectively mitigates platelet aggregation and has been shown to enhance reendothelialization after vascular injury in diabetic rat models by promoting autophagy. Its biological activity makes Notoginsenoside Fc a valuable reagent for research in cardiovascular health and vascular regeneration. -
PAFR Antagonist
Benafentrine maleate is an antagonist of the platelet activating factor receptor (PAFR) and a phosphodiesterase 4 (PDE4) inhibitor. This compound is primarily utilized in research focused on inflammation, neurological disorders, and cardiovascular diseases. By blocking PAFR activity, Benafentrine maleate has the potential to modulate various cellular responses associated with these conditions, making it a valuable tool in pharmacological studies. -
Platelet Aggregation Inhibitor
SCH 38519 is a potent platelet aggregation inhibitor that effectively inhibits thrombin-induced aggregation of human platelets, exhibiting an IC50 of 68 μg/mL. In addition to its antiplatelet activity, SCH 38519 demonstrates antibacterial properties against both Gram-positive and Gram-negative bacteria. This compound is valuable for research applications focused on thrombosis, cardiovascular diseases, and bacterial infections. -
Platelet-Activating Factor Antagonist
Acopafant is a potent platelet-activating factor antagonist that plays a critical role in modulating inflammatory responses. Its ability to inhibit human immunodeficiency virus (HIV) expression in chronically infected cells highlights its potential utility in HIV research. Acopafant is valuable for studies investigating the mechanisms of HIV infection and the development of therapeutics targeting viral latency and reactivation. -
PAFR Antagonist
(Rac)-Modipafant is a selective, long-acting irreversible antagonist of the platelet activating factor receptor (PAFR). This compound demonstrates significant biological activity by effectively inhibiting PAFR-mediated pathways, which plays a critical role in regulating inflammatory responses. Research applications include the investigation of dengue virus infection mechanisms and the potential therapeutic effects of PAFR blockade in various inflammatory diseases. -
Platelet Aggregation Inhibitor
D-RGDW is a synthetic peptide containing the Arg-Gly-Asp (RGD) sequence, which targets the αIIbβ3 integrin. It effectively inhibits platelet aggregation, making it a valuable tool for research into thrombosis and hemostasis. D-RGDW can be utilized in various biochemical studies focused on vascular biology and the mechanisms of platelet activation. -
Glycoprotein IIb/IIIa Receptor/Platelet Aggregation Antagonist
Lamifiban TFA is a nonpeptide antagonist of the glycoprotein IIb/IIIa receptor, which plays a critical role in platelet aggregation. This compound effectively inhibits platelet aggregation and has shown potential in enhancing thrombolytic therapy to restore coronary arterial patency. Lamifiban TFA is a valuable tool for research in acute coronary syndromes and related cardiovascular conditions. -
Glycoprotein IIb/IIIa Receptor/Platelet Aggregation Antagonist
Lamifiban is a nonpeptide antagonist of the glycoprotein IIb/IIIa receptor, targeting platelet aggregation processes. It has demonstrated efficacy in restoring coronary arterial patency when used in combination with thrombolytic therapy. Lamifiban is a valuable compound for research focused on acute coronary syndromes and related cardiovascular conditions. -
Glycoprotein IIb-IIIa/Platelet Aggregation Inhibitor
Variabilin is a potent antagonist of glycoprotein IIb-IIIa, functioning primarily as a platelet aggregation inhibitor. Isolated from the hard tick Dermacentor variabilis, Variabilin effectively inhibits platelet aggregation induced by various agonists, including ADP, collagen, and thrombin receptor peptide SFLLRNP. Additionally, it hinders platelet adhesion to immobilized fibrinogen (Fg) and blocks the binding of purified human GPIIb-IIIa to immobilized Fg. This compound is valuable for research applications in hematology and thrombosis. -
Platelet Aggregation Inhibitor
U-51605 is a platelet aggregation inhibitor that targets thromboxane synthesis. It also functions as a prostaglandin I2 synthase inhibitor and has been shown to block retinal vasodilation responses induced by nitric oxide donors like NOR3. This reagent is valuable for research applications focusing on cardiovascular health and vascular biology. -
platelet aggregation inhibitor
Trifenagrel is an orally active platelet aggregation inhibitor that targets the pathways induced by arachidonic acid and collagen. It demonstrates significant biological activity, with ED50 values of 1.4 mg/kg and 9.4 mg/kg for the inhibition of AA- and collagen-induced platelet aggregation in guinea pigs, respectively. This compound serves as a valuable tool in cardiovascular research and the study of thrombotic disorders. -
Platelet-activating Factor Receptor (PAFR) Inhibitor
TSI-01 is a selective inhibitor of the Platelet-activating Factor Receptor (PAFR), targeting lysophosphatidylcholine acyltransferase (LPCAT)2. This compound exhibits a potent inhibitory effect with an IC50 of 0.47 μM for human LPCAT2, significantly more effective than its activity on LPCAT1 (IC50 = 3.02 μM). TSI-01 effectively suppresses PAF biosynthesis in mouse peritoneal macrophages when stimulated with a calcium ionophore at a concentration of 60 μM. This makes TSI-01 a valuable tool for investigating inflammatory processes and related conditions in research applications. -
PAFR Antagonist
MK 287 is a potent and selective antagonist of the platelet-activating factor receptor (PAFR). It effectively inhibits [3H]C18-PAF binding to human platelets, polymorphonuclear leukocytes (PMNs), and lung membranes, with K1 values of 6.1, 3.2, and 5.49 nM, respectively. MK 287 also demonstrates the ability to inhibit PAF-induced platelet aggregation and elastase release from PMNs, with ED50 values of 56, 1.5, and 4.4 nM. This compound is valuable for research focused on cardiovascular diseases, including thrombosis. -
PAF Antagonist
CV-6209 is a potent antagonist of platelet activating factor (PAF) that effectively inhibits PAF-induced aggregation in both rabbit and human platelets, demonstrating IC50 values of 75 nM and 170 nM, respectively. Additionally, CV-6209 has been shown to inhibit PAF-induced hypotension in rat models. This compound is valuable for research focused on platelet function, cardiovascular responses, and PAF-related pathways. -
PAF Agonist
Carbamyl-PAF is an analog and agonist of platelet-activating factor (PAF). It exhibits potent biological activity by stimulating PAF receptors, which play a crucial role in mediating inflammatory responses. Due to its stability and resistance to metabolism in Raji lymphoblasts at 37°C, Carbamyl-PAF is an effective reagent for studying PAF-related signaling pathways and inflammation mechanisms. -
PAF Receptor Antagonist
MoTP is a selective antagonist of the platelet-activating factor (PAF) receptor, known for its ability to induce melanocyte ablation. This compound exhibits significant biological activity that can be leveraged in cancer research, offering insights into melanocyte regulation and tumor microenvironment interactions. MoTP is a valuable reagent for studies aimed at understanding the role of PAF signaling in tumor biology and potential therapeutic strategies. -
Platelet-activating Factor Antagonist
Kadsurenone is a lignan that acts as a specific antagonist of platelet-activating factor (PAF). By inhibiting PAF, Kadsurenone demonstrates potential anti-inflammatory and anti-platelet effects. This compound is commonly explored in research related to cardiovascular disorders and other conditions associated with platelet activation. Kadsurenone can be obtained from the stem of Piper kadsura, providing a natural source for studying its biological activities. -
Platelet Aggregation Inhibitor
2-Acetylbenzoic acid is a derivative of benzoic acid that functions as a weak inhibitor of platelet aggregation. It specifically inhibits adenosine 5'-diphosphate (ADP)-induced platelet aggregation, making it valuable for research in cardiovascular biology and thrombotic disorders. This compound can be utilized to study the role of platelet activation in various disease models and therapeutic interventions. -
PAF Antagonist
TCV-309 chloride is a highly effective antagonist of platelet-activating factor (PAF). It demonstrates specificity in inhibiting PAF-induced aggregation in both rabbit and human platelets, with IC50 values of 33 nM, 58 nM, and 27 nM for the corresponding assays. Additionally, TCV-309 chloride has exhibited potential therapeutic benefits in conditions such as anaphylactic shock, making it a valuable tool for research into PAF-related pathways and inflammatory responses. -
PAF Agonist
Butanoyl PAF is a potent platelet-activating factor (PAF) agonist that retains over 10% of PAF's biological activity. This compound is found in significantly higher concentrations in oxidized low-density lipoprotein compared to enzymatically generated PAF, exceeding it by more than 100-fold. Butanoyl PAF is valuable in research applications aimed at understanding PAF-mediated signaling pathways and their roles in various physiological and pathological processes. -
PAF Receptor Antagonist
α-Bulnesene is a potent PAF receptor antagonist, exhibiting an IC50 of 17.62 μM. Isolated from Pogostemon cablin, it demonstrates significant inhibitory activity against platelet-activating factor and arachidonic acid-induced platelet aggregation in rabbits. This compound is valuable for research exploring the modulation of platelet function and related inflammatory processes. -
PAF Antagonist
Modipafant is a potent and selective platelet-activating factor (PAF) antagonist, known as UK-80067, and represents the (+)-enantiomer of UK-74505. This compound displays approximately double the intrinsic potency of its predecessor, making it a valuable tool in exploring PAF-related biological pathways. Modipafant is primarily utilized in research applications focused on inflammation, cardiovascular disease, and related therapeutic areas. -
PAF Antagonist
CL-184005 is a potent platelet-activating factor (PAF) antagonist that effectively inhibits PAF-induced platelet aggregation, with IC50 values of 600 nM and 510 nM in human and rabbit platelet-rich plasma, respectively. This compound has demonstrated protective effects against endotoxin-induced gastrointestinal damage and hypotension in rat models. Additionally, CL-184005 shows promise in mitigating the effects of Gram-negative bacterial sepsis, making it a valuable tool for research in inflammatory and infectious disease models. -
PAF Antagonist
Clotizolam is a thienobenzodiazepine derivative that acts as an antagonist of platelet-activating factor (PAF). It exhibits sedative, anxiolytic, anticonvulsant, and muscle relaxant properties, making it useful in various research applications related to anxiety and seizure disorders. This compound can be employed in studies aimed at understanding the mechanisms of PAF signaling and its implications in neurological and psychological conditions.
